Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 490

1.

Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.

Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ.

Blood. 1993 Jun 1;81(11):2925-35.

2.

A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.

Jacquemin M, Lavend'homme R, Benhida A, Vanzieleghem B, d'Oiron R, Lavergne JM, Brackmann HH, Schwaab R, VandenDriessche T, Chuah MK, Hoylaerts M, Gilles JG, Peerlinck K, Vermylen J, Saint-Remy JM.

Blood. 2000 Aug 1;96(3):958-65.

3.

Structure and function of the factor VIII gene and protein.

Thompson AR.

Semin Thromb Hemost. 2003 Feb;29(1):11-22. Review.

PMID:
12640560
5.

Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.

Gale AJ, Radtke KP, Cunningham MA, Chamberlain D, Pellequer JL, Griffin JH.

J Thromb Haemost. 2006 Jun;4(6):1315-22.

6.

Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: discordant in vitro and in vivo activity.

Mertens K, Donath MJ, van Leen RW, de Keyzer-Nellen MJ, Verbeet MP, Klaasse Bos JM, Leyte A, van Mourik JA.

Br J Haematol. 1993 Sep;85(1):133-42.

PMID:
8251380
7.

Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII.

Tagliavacca L, Moon N, Dunham WR, Kaufman RJ.

J Biol Chem. 1997 Oct 24;272(43):27428-34.

8.
10.
11.

Role of the B domain for factor VIII and factor V expression and function.

Pittman DD, Marquette KA, Kaufman RJ.

Blood. 1994 Dec 15;84(12):4214-25.

12.

Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency.

Plantier JL, Rolli V, Ducasse C, Dargaud Y, Enjolras N, Boukerche H, NĂ©grier C.

J Thromb Haemost. 2010 Feb;8(2):286-93. doi: 10.1111/j.1538-7836.2009.03675.x. Epub 2009 Oct 30.

13.

A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage.

Pittman DD, Millenson M, Marquette K, Bauer K, Kaufman RJ.

Blood. 1992 Jan 15;79(2):389-97.

14.

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.

Jacquemin M, Benhida A, Peerlinck K, Desqueper B, Vander Elst L, Lavend'homme R, d'Oiron R, Schwaab R, Bakkus M, Thielemans K, Gilles JG, Vermylen J, Saint-Remy JM.

Blood. 2000 Jan 1;95(1):156-63.

15.

Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.

Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K.

Thromb Haemost. 1996 Nov;76(5):749-54.

PMID:
8950785
16.

A role for the C2 domain of factor VIII in binding to von Willebrand factor.

Saenko EL, Shima M, Rajalakshmi KJ, Scandella D.

J Biol Chem. 1994 Apr 15;269(15):11601-5.

18.

Bioengineering of coagulation factor VIII for improved secretion.

Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW.

Blood. 2004 May 1;103(9):3412-9. Epub 2004 Jan 15.

19.

Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa.

Donath MJ, de Laaf RT, Biessels PT, Lenting PJ, van de Loo JW, van Mourik JA, Voorberg J, Mertens K.

Biochem J. 1995 Nov 15;312 ( Pt 1):49-55.

20.

The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein.

Lenting PJ, Neels JG, van den Berg BM, Clijsters PP, Meijerman DW, Pannekoek H, van Mourik JA, Mertens K, van Zonneveld AJ.

J Biol Chem. 1999 Aug 20;274(34):23734-9.

Supplemental Content

Support Center